David Chien has over 26 years of experience in the field of medical equipment, focusing primarily on corporate operations and sales and marketing. Chien is currently Chairman of the Board of OrbusNeich. He is devoted to the field of interventional cardiology and is the Vice Chairman of the Chien Foundation, a charitable organization with the vision of contributing to, and improving, the practice of cardiovascular medicine for physicians in the Asia-Pacific region. Apart from his interest in the medical equipment frontier, he also has 16 years of experience in real estate property investment, development and management in both Hong Kong and China. Until 2014 he held a position as Director of the Board of a listed Hong Kong company. He was responsible for organizing and managing the operations of the real estate property division of that company. Chien holds a BA in Business Administration from York University, Ontario, Canada.
Wayne Johnson has over 33 years of medical device experience, primarily in the areas of general management, operations, and product development. Johnson is currently President, Chief Executive Officer and a Director of the Board of OrbusNeich. Before working at OrbusNeich, he was President and CEO of Sutura, Inc., a development stage company based in Fountain Valley, California, focused on commercializing suture-mediated wound closure products. Preceding Sutura, he was President and CEO of Prostec, LLC (a division of Syntheon, LLC), dedicated to devices for prostate brachytherapy. Prior to Prostec, he was employed by Cordis for 18 years, during which time he held various roles of increasing responsibility including Vice President and General Manager of Cordis' largest facility. He was also a member of the Cordis operating board as Vice President of worldwide operations. Since 2012 he has been a member of the board of directors of Microvisk Technologies Limited, a United Kingdom based company developing medical diagnostic devices. Johnson holds a BS in Biology and both an MBA and an MS in Management from Rensselaer Polytechnic Institute.
Christophe Lee has over 24 years of experience in the financial service sector. Lee joined OrbusNeich in 2012 and is currently Vice President, Chief Financial Officer and a Director of the Board of OrbusNeich. Prior to joining OrbusNeich, Lee worked at FrontPoint Partners, Sun Hung Kai Financial, Goldman Sachs and Bankers Trust. Lee served as the Chairman of the Hong Kong Chapter of The Alternative Investment Management Association (AIMA) from 2003 to 2012. He was appointed by the HKSAR government to serve on the Advisory Committee of the Securities and Futures Commission (SFC) from 2007 to 2009, and since March 2013 to serve on the New Business Committee of the Financial Services Development Council. Lee was also a committee member of the Hong Kong Trade Development Council Financial Services Advisory Committee from 2007 to 2011. He is a graduate of the University of Pennsylvania.
Scott Addonizio has over 20 years of experience in the medical device industry having served in key positions in several areas, including research and development, quality, manufacturing, marketing and most recently operations. Addonizio is currently Vice President and General Manager, Shenzhen Operations and a Director of the Board of OrbusNeich. He started his career as a design engineer working for Boston Scientific and as an industrial design engineer for Cordis Endovascular. In 1998, Addonizio joined Orbus as a project manager and is the primary patent holder for the “stent having dual helical design”, which serves as the backbone for all OrbusNeich stent platforms. In 2005 Addonizio was assigned the position of General Manager, Director of Operations for OrbusNeich Shenzhen, China. Since his appointment, he has successfully managed and maintained operations in China and has familiarized himself with the local language, customs and most importantly the business culture of the region. Addonizio holds a degree in Packaging Engineering from Michigan State University and an MBA in International Business from the University of Miami.
Alain Aimonetti has over 24 years of medical device sales and marketing experience. Aimonetti held a variety of senior roles in the cardio and endovascular medical devices industry in this period. Aimonetti joined OrbusNeich after 13 years at Biotronik, where he was the vice president of global sales and business development at Biotronik between 2007-2014 and the country manager for vascular intervention France and Africa between 2002 and 2007. Alain has devoted himself to the vascular intervention field throughout his career. At the earlier stage of his career, from 1993 to 1996, he was the country manager vascular intervention Africa and Canada at Cordis (a Johnson & Johnson company), and was subsequently appointed as the global marketing manager at Boston Scientific and the vice president of sales and marketing for EMEA at SUTURA BV. Before to join the industry Alain Aimonetti was a Senior Technician in a Catheterization Lab in France.
Takeshi Ohba has over 20 years of medical device experience and has served as the President of OrbusNeich Medical KK since 2002. Prior to joining, he worked at TUV Rheinland Japan as General Manager, at Jansen Pharmaceutical Japan (a Johnson & Johnson company) as a director in the sales promotion department and at Johnson & Johnson Medical K.K. (Cordis Cardiology) as a director of the marketing department. He graduated from Keio University, Tokyo and holds a Marketing degree from the Waseda University Business School.
Stephen Rowland joined OrbusNeich after a 14 year tenure at Cordis, where he was Vice President of Research and Development. Rowland was also Vice President and General Manager of Cordis Endovascular Systems, a separate business unit of Cordis focused on instrumentation to treat neurovascular diseases. He was responsible for all aspects of this start-up business including sales, marketing, development, strategic planning, and administration. His other experiences at Cordis included major contributions to advanced research and development across a variety of Cordis product initiatives. He is the inventor of nine issued U.S. patents, two published patent applications, and several other pending applications. Rowland holds a BS in Biology from West Virginia Wesleyan College and a PhD in Bio-engineering from the University of Utah.
Robert Cottone co-founded Orbus Medical Technologies in 1996, the predecessor of OrbusNeich Medical. His prior experience includes working for Cordis Corporation (a Johnson & Johnson company) from 1988 until 1996. While at Cordis, Cottone managed the development, engineering, and manufacturing of several key product programs including diagnostic catheters, endomyocardial biopsy forceps, and peripheral vascular stents. In his current capacity as Vice President of Intellectual Property and Technologies at OrbusNeich, he oversees the global creation, construction, filing and prosecution of all OrbusNeich patents, copyrights and trademarks. He is instrumental in the concept, design and development for all stent and stent coating programs, and provides leadership and technical expertise to ensure OrbusNeich products meet clinical and market requirements. Cottone has a Bachelor of Science in Industrial Engineering from Florida International University. He is the named inventor of 31 issued U.S. patents and 56 U.S. patent applications, along with all of their corresponding international patent filings.
Jim Clossick's background includes over 26 years of medical device experience. He specializes in international regulatory affairs, design control, process validation engineering, design of experiments, failure mode and effects analysis, customer requirements analysis, and quality functional deployment (QFD).Clossick provides leadership for seeking regulatory approvals for cardiovascular devices, including combination products. He holds two U.S. patents for device design. Clossick is a certified quality engineer, a certified Six Sigma Black Belt, and a certified QFD facilitator. In addition to his BS degree in Mechanical Engineering from the Missouri University of Science and Technology-Rolla, he has undertaken additional studies in Biomedical Engineering.